1. Home
  2. RNXT vs FAAS Comparison

RNXT vs FAAS Comparison

Compare RNXT & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • FAAS
  • Stock Information
  • Founded
  • RNXT 2012
  • FAAS 2021
  • Country
  • RNXT United States
  • FAAS Indonesia
  • Employees
  • RNXT N/A
  • FAAS N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • FAAS
  • Sector
  • RNXT Health Care
  • FAAS
  • Exchange
  • RNXT Nasdaq
  • FAAS NYSE
  • Market Cap
  • RNXT 31.6M
  • FAAS 34.6M
  • IPO Year
  • RNXT 2021
  • FAAS N/A
  • Fundamental
  • Price
  • RNXT $1.15
  • FAAS $0.60
  • Analyst Decision
  • RNXT Strong Buy
  • FAAS
  • Analyst Count
  • RNXT 1
  • FAAS 0
  • Target Price
  • RNXT $9.00
  • FAAS N/A
  • AVG Volume (30 Days)
  • RNXT 195.7K
  • FAAS 431.5K
  • Earning Date
  • RNXT 03-31-2025
  • FAAS 09-17-2024
  • Dividend Yield
  • RNXT N/A
  • FAAS N/A
  • EPS Growth
  • RNXT N/A
  • FAAS N/A
  • EPS
  • RNXT N/A
  • FAAS N/A
  • Revenue
  • RNXT N/A
  • FAAS $57,730,593.00
  • Revenue This Year
  • RNXT N/A
  • FAAS N/A
  • Revenue Next Year
  • RNXT N/A
  • FAAS N/A
  • P/E Ratio
  • RNXT N/A
  • FAAS N/A
  • Revenue Growth
  • RNXT N/A
  • FAAS 38.16
  • 52 Week Low
  • RNXT $0.77
  • FAAS $0.38
  • 52 Week High
  • RNXT $1.86
  • FAAS $12.97
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 58.08
  • FAAS 41.84
  • Support Level
  • RNXT $1.32
  • FAAS $0.43
  • Resistance Level
  • RNXT $1.40
  • FAAS $0.55
  • Average True Range (ATR)
  • RNXT 0.11
  • FAAS 0.10
  • MACD
  • RNXT 0.00
  • FAAS -0.01
  • Stochastic Oscillator
  • RNXT 39.47
  • FAAS 19.95

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About FAAS DIGIASIA CORP

DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.

Share on Social Networks: